Please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech reported Q2 FY26 standalone revenue from operations of Rs 1,301.66 lakh, up about 8% from Rs 1,203.51 lakh a year ago. However, total income fell to Rs 1,315.05 lakh from Rs 1,666.61 lakh because other income dropped sharply from Rs 463.10 lakh to Rs 13.39 lakh (base quarter had a one-time gain). Standalone profit after tax plunged to Rs 86.92 lakh from Rs 531.27 lakh, with EPS at Rs 0.45 vs Rs 3.56. For the half-year, operating revenue grew nearly 15% to Rs 2,543.52 lakh, but PAT fell to Rs 224.24 lakh from Rs 549.06 lakh. The board allotted 22.07 lakh equity shares on conversion of warrants during the quarter. Auditor P. Murali & Co. issued an unmodified review report on both standalone and consolidated results.
Shareholders should note the headline PAT collapse is largely a base-effect distortion from last year's one-time other income; underlying operating revenue is still growing. However, cash flow from operations swung sharply negative (Rs -965.68 lakh standalone, Rs -1,720.80 lakh consolidated vs positive last year), pointing to working-capital strain that may weigh on sentiment despite the clean auditor opinion.